Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection,JAMA

当前位置： X-MOL 学术 › JAMA › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection
JAMA ( IF 63.1 ) Pub Date : 2022-02-01 , DOI: 10.1001/jama.2021.24939
Meagan P O'Brien ₁ , Eduardo Forleo-Neto ₁ , Neena Sarkar ₁ , Flonza Isa ₁ , Peijie Hou ₁ , Kuo-Chen Chan ₁ , Bret J Musser ₁ , Katharine J Bar _{2,

3} , Ruanne V Barnabas _{4,

5,

6,

7} , Dan H Barouch ₈ , Myron S Cohen ₉ , Christopher B Hurt ₉ , Dale R Burwen ₁₀ , Mary A Marovich ₁₀ , Elizabeth R Brown _{7,

11} , Ingeborg Heirman ₁ , John D Davis ₁ , Kenneth C Turner ₁ , Divya Ramesh ₁ , Adnan Mahmood ₁ , Andrea T Hooper ₁ , Jennifer D Hamilton ₁ , Yunji Kim ₁ , Lisa A Purcell ₁ , Alina Baum ₁ , Christos A Kyratsous ₁ , James Krainson ₁₂ , Richard Perez-Perez ₁₃ , Rizwana Mohseni ₁₄ , Bari Kowal ₁ , A Thomas DiCioccio ₁ , Gregory P Geba ₁ , Neil Stahl ₁ , Leah Lipsich ₁ , Ned Braunstein ₁ , Gary Herman ₁ , George D Yancopoulos ₁ , David M Weinreich ₁ ,

Affiliation

Regeneron Pharmaceuticals Inc, Tarrytown, New York.
Department of Medicine, University of Pennsylvania, Philadelphia.
Department of Microbiology, University of Pennsylvania, Philadelphia.
Department of Global Health, University of Washington, Seattle.
Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Department of Epidemiology, University of Washington, Seattle.
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
Department of Biostatistics, University of Washington, Seattle.
Clinical Trials of Florida LLC, Miami.
Medical Research of Westchester, Miami, Florida.
Catalina Research Institute LLC, Montclair, California.

This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living with an infected household contact.

中文翻译：

Casirivimab 和 Imdevimab 组合以及 SARS-CoV-2 感染中症状性 COVID-19 的发展

这项随机试验评估了单剂量皮下注射 casirivimab 和 imdevimab 抗体组合与安慰剂相比，对无症状 SARS-CoV-2 逆转录酶定量聚合酶链反应阳性的感染者的 28 天进展为有症状的 COVID-19 的影响家庭联系。

更新日期：2022-02-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文